 |
|
|
| |
High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence
|
| |
| |
IDWeek 2021, September 29-October 3, 2021
Kristen Andreatta, Michelle L. D'Antoni, Silvia Chang, Aiyappa Parvangada, Ross Martin, Christiana Blair, Sean E. Collins, Kirsten L. White - Gilead Sciences, Inc., Foster City, CA
References: 1. EACS European AIDS Clinical Society. Guidelines Version 9.1, Oct 2018; 2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Dept of Health and Human Services; 2021; 3. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Dept of Health and Human Services; 2020; 4. Saag MS, et al. JAMA 2018;320:379-96; 5. Hagins D, et al. JAIDS 2021;88:86-95; 6. Armenia D, et al. J Clin Virol 2018;104:61-4; 7. Cutrell AG, et al. AIDS 2021;35:1333-42; 8. Younas M, et al. Front Immunol 2021;12:663843; 9. Zoufaly A, et al. HIV Med 2014;15:4449-57; 10. Gagliardini R, et al. Open Forum Infect Dis 2018;5:ofy113; 11. Grennan JT, et al. J Infect Dis 2012;205:1230-8; 12. Porter DP, et al. Antivir Ther 2017;22:495-502; 13. Sax PE, et al. CROI 2020, poster 495; 14. Wensing AM, et al. Top Antivir Med 2017; 24:132-41. Acknowledgments: We extend our thanks to the participants, their families, and participating study investigators and staff. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
